Reactions Weekly

, Volume 1206, Issue 1, pp 3–3 | Cite as

... while UK MHRA releases new safety overview

News item
  • 8 Downloads

Keywords

Melanoma Liver Injury Progressive Multifocal Leukoencephalopathy Natalizumab Safety Study 

REFERENCE

  1. 1.
    MHRA, CHM.Natalizumab (Tysabri): safety overview - progressive multifocal leukoencephalopathy, hypersensitivity, and hepatotoxicity. Drug Safety Update 1: 2-4, No. 11, Jun 2008Google Scholar

Copyright information

© Adis International limited or Adis Data Information BV 2008

Personalised recommendations